Fichero a descargar de la publicaciÃ³n mostrada - Sociedad ...

More documents

Recommendations

Info

Octubre 2011 INFECCIONES RELACIONADAS CON CATÉTERES VASCULARES Pág. 46______________________________________________________________________________75. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemiaamong patients with end-stage renal disease. Clin Infect Dis 2006; 42:66-72.76. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia andendocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.77. Marco F, de la María CG, Armero Y, et al. Daptomycin is effective in treatment of experimental endocarditisdue to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob AgentsChemother 2008; 52:2538-43.78. García de la María C, Marco F, Armero Y, et al. Daptomycin is effective for treatment of experimentalendocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis. AntimicrobAgents Chemother 2010; 54:2781-6.79. Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of Grampositivecatheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2010; 36:182-6.80. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, De FD, Viscoli C. High-dose daptomycin in documentedStaphylococcus aureus infections. Int J Antimicrob Agents 2010; 36:459-61.81. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. Daptomycin-oxacillin combinations intreatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistantStaphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob AgentsChemother 2010; 54:3161-9.82. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. In vitro prevention of the emergence of daptomycinresistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid orampicillin. Int J Antimicrob Agents 2010; 35:451-6.83. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistantStaphylococcus aureus. Antimicrob Agents Chemother 2004; 48:2871-5.84. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortalityassociated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a metaanalysis.Clin Infect Dis 2003; 36:53-9.85. Francioli P, Clement M, Geroulanos S, et al. Ceftazidime in severe infections: a Swiss multicentre study. JAntimicrob Chemother 1983; 12 Suppl A:139-46.86. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B fortreatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin MicrobiolInfect Dis 1997; 16:337-45.87. Alexandraki I, Sullivan R, Zaiden R, et al. Blood culture isolates in hemodialysis vascular catheter-relatedbacteremia. Am J Med Sci 2008; 336:297-302.88. Allon M. Treatment guidelines for dialysis catheter-related bacteremia: an update. Am J Kidney Dis 2009;54:13-7.89. Azanza JR, García-Blázquez E, Sádaba B, Manubens A. Uso de antimicrobianos en pacientes con insuficienciarenal o hepática. Enferm Infecc Microbiol Clin 2009; 27:593-9.90. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC. Cefazolin in chronic hemodialysispatients: a safe, effective alternative to vancomycin. Am J Kidney Dis 1998; 32:401-9.91. Tokars JI. Vancomycin use and antimicrobial resistance in hemodialysis centers. Am J Kidney Dis 1998;32:521-3.92. Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections:efficacy and blood concentrations. Am J Kidney Dis 1998; 32:410-4.
Octubre 2011 INFECCIONES RELACIONADAS CON CATÉTERES VASCULARES Pág. 47______________________________________________________________________________93. Stryjewski ME, Szczech LA, Benjamin DK Jr., et al. Use of vancomycin or first-generation cephalosporins forthe treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureusbacteremia. Clin Infect Dis 2007; 44:190-6.94. Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial2008; 21:63-70.95. Smith PF, Morse GD. Accuracy of measured vancomycin serum concentrations in patients with end-stage renaldisease. Ann Pharmacother 1999; 33:1329-35.96. Chang FY, Peacock JE Jr., Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact ofantibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.97. Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. Flucloxacillin dosing in critically ill patients withhypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65:1771-8.98. Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial resistanceSurveillance Network (EARS-Net). 2009. Ref Type: Electronic Citation.99. Mensa J, Barberan J, Llinares P, et al. [Guidelines for the treatment on infections caused by methicillin-resistantStaphylococcus aureus]. Rev Esp Quimioter 2008; 21:234-58.100. Almirante B, Rodríguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candidabloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J ClinMicrobiol 2005; 43:1829-35.101. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-relatedbloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48:203-12.102. Kaka AS, Rueda AM, Shelburne SA III, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orallyavailable agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:680-3.103. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for thetreatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-8.104. Goldberg E, Paul M, Talker O, et al. Co-trimoxazole versus vancomycin for the treatment of methicillinresistantStaphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother 2010;65:1779-83.105. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis inpatients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496-503.106. Cosgrove SE, Vigliani GA, Fowler VG Jr., et al. Initial low-dose gentamicin for Staphylococcus aureusbacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713-21.107. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditisin intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; 2:1071-3.108. Schrenzel J, Harbarth S, Schockmel G, et al. A randomized clinical trial to compare fleroxacin-rifampicin withflucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004; 39:1285-92.109. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditisin injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101:68-76.110. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valveinfective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2463-7.111. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. ClinInfect Dis 2008; 46 Suppl 5:S386-93.
Page 1 and 2: AVANCES ENENFERMEDADES INFECCIOSASP
Page 3 and 4: Octubre 2011 INFECCIONES RELACIONAD
Page 45: Octubre 2011 INFECCIONES RELACIONAD

Fichero a descargar de la publicaciÃ³n mostrada - Sociedad ...

Create successful ePaper yourself

Delete template?

Save as template?